Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) reported Wednesday that the company appointed Andreas Rummelt to its board of directors, according to Associated Press.
Rummelt was a member of the executive committee of Novartis (NYSE: NVS) from 2006 to 2010, where he most recently served as group head of quality assurance and technical operations.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Rummelt also served as CEO of Sandoz, the generics division of Novartis, from 2004-2008.
Early in the month, Alexion reported a rise in its fiscal fourth-quarter profit, topping analyst expectations. The company earned $237.1 million, or $2.59 per share, in the latest period, helped by a tax gain of $214.5 million.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
